CJC-1295 Side Effects: Human Trial Rates and What the FDA Found
Most CJC-1295 side effect pages are built from vendor copy and forum posts. This one starts from the trial papers and the FDA's own review, and says plainly how small the evidence is: two early trials, 66 volunteers, at most three doses each. Everything below is research use information. It is not medical advice, and none of it replaces a clinician who can see your bloodwork and history.
DAC and No-DAC Are Different Exposures
Best vendor for CJC-1295 (no DAC) right now: Amino Club
10mg vial, $59.99 per vial ($6.00 per mg), list price checked 2026-09-08. The vendor Bureau readers order from most this year, with a batch COA on every product page. Partner code 100 at checkout takes 20% off there, and keeps the order counted for the Bureau. Research use only.
Check price at Amino Club Compare all vendors Black FridayCyber Monday 40% off, applied by our link (was 20%) code 100 ends 30 NovThe compound in the human trials was the long-acting version, CJC-1295 with DAC, which binds to albumin in the blood. In Teichman's 2006 trial that gave it a half-life of 5.8 to 8.1 days and kept IGF-1 raised for 9 to 11 days after one injection. CJC-1295 without DAC lacks that albumin-binding group. The CJC-1295 dosage guide covers how the two are dosed. For safety the point is simpler: the FDA's 2024 review found no clinical safety information on the forms without DAC, so every rate below describes the DAC version only, and anything said about the no-DAC version is inference. If you want to compare suppliers once you have read the evidence, the CJC-1295 and ipamorelin buyer's guide lays out the options.
Not sure which of these you actually need?
Answer five questions about your goal, experience and budget and the Stack Builder shows you a matched research protocol on screen, with the compounds, cycle shape and vendor picks from the vendors we score.
Build your stack, 2 minutesCJC-1295 Side Effects at a Glance
The table gives each effect with the rate the trial paper reported. The single-dose trial (study 1) had 35 people on CJC-1295 and 7 on placebo. The repeat-dose trial (study 2) had 20 on the drug and 4 on placebo, given 2 or 3 weekly or biweekly doses. Doses ranged from 20 to 250 micrograms per kilogram.
| Effect | What the trial reported | Source |
|---|---|---|
| Any adverse event | Single dose: 94% (33 of 35) on CJC-1295 versus 29% (2 of 7) on placebo. All mild to moderate; none needed medical treatment. | Teichman 2006 |
| Injection site reactions (irritation, redness, hardening, pain, itching) | About 70% after one dose, rare on placebo. Transient, up to several hours, with hardening lasting up to 5 days after higher doses. Every treated person in the repeat-dose trial, all mild. | Teichman 2006 |
| Hives-like rash at the injection site | Almost 30% after one dose, not related to dose. | Teichman 2006 |
| Headache | 63% on CJC-1295 versus 14% on placebo after one dose. Repeat-dose trial: 20 to 80% depending on the dose group, 50% on placebo. | Teichman 2006 |
| Diarrhea or loose stools | 43% after one dose, none on placebo; more common at the higher doses. | Teichman 2006 |
| Flushing, warmth, brief low blood pressure | 30% after one dose. In the repeat-dose trial flushing hit 40% after the low dose and 100% after the high dose, began within 30 minutes and resolved within 1 to 2 hours. None on placebo. | Teichman 2006 |
| Nausea or abdominal pain | 20% in the repeat-dose trial, drug group only. | Teichman 2006 |
| Dizziness with low blood pressure | Two people after a first 30 microgram per kilogram dose; it resolved and did not return on later doses. | Teichman 2006 |
| Leg muscle contractions and some loss of coordination | One person after the second biweekly dose, mild, gone in under 24 hours. | Teichman 2006 |
| Faster heart rate, redness and tenderness at the injection site | Single dose of 60 or 90 micrograms per kilogram in healthy men. The heart rate rise was dose dependent; no serious events. Rates are not in the abstract. | Ionescu 2006, as summarised in the FDA briefing |
| Antibodies, ECG, glucose, liver tests | No significant antibody formation; no consistent changes in glucose, liver tests or ECG in either study. | Teichman 2006 |
| Edema, joint pain, glucose intolerance | The authors state none of the subjects experienced these. | Teichman 2006 |
| Serious adverse reactions | None reported in either study. | Teichman 2006 abstract |
How Small the Human Trials Were
Treat every percentage above as rough. Study 1 enrolled 42 people and study 2 enrolled 24, ages 21 to 61, with 44% men and a body mass index of 30 or less. The dose groups held five treated people each (20 at 125 micrograms per kilogram), so one person is worth 20 percentage points in most groups, and the "100%" flushing figure comes from a handful of people. The placebo group in the repeat-dose trial was four people, which is why 50% of them reporting headache means little. Three people left the studies early: two after mild injection site reactions and one after multiple mild effects from a single dose. The authors call the compound well tolerated, particularly at 30 or 60 micrograms per kilogram, and report that adverse events did not differ by sex. The Ionescu study added single doses in healthy men aged 20 to 40. In its 2024 review the FDA counted 63 healthy adults exposed to CJC-1295 DAC across the published studies, 73% of them to a single injection and none to more than four, and called the studies small and short.
That leaves what the trials could not show. Nothing here speaks to months of use, to the doses and injection schedules people use outside a protocol, or to people with heart disease, diabetes or other conditions. Reports of water retention, bloating or hunger on vendor and clinic pages have no rate behind them. Fluid retention is a labeled risk of approved growth hormone, and the Teichman authors saw none of it in their subjects after at most three doses, so both statements stand until longer data exist.
The 2006 Phase 2 Trial and the Participant Death
This is the part of the record most vendor pages leave out. In 2006 ConjuChem ran a separate Phase 2 study of CJC-1295 in 192 people with HIV-related visceral obesity, a multicentre, randomised, placebo-controlled, double-blind trial at sites in North and South America. Participants got weekly injections: a three-week escalation to 120 or 240 micrograms per kilogram, then nine more weeks.
| What happened | What is documented |
|---|---|
| Stopping the study | ConjuChem stopped the study on 17 July 2006. At the time it said only that the participant who died was at a site in Argentina, and that the cause of death and any link to the drug were being investigated (aidsmap, 31 July 2006). |
| The event, as reported | The FDA's briefing cites anecdotal reports: two hours after an 11th weekly dose the participant complained of chest discomfort, an ECG confirmed an acute heart attack, and the participant died about an hour later. |
| Attending physician's explanation | The most likely explanation was asymptomatic coronary artery disease with plaque rupture and occlusion, as relayed in the same anecdotal reports. |
| What was published | Nothing. The FDA states the study was terminated and its data have not been published, and that no further information on other participants or adverse events was available. |
Two things are true together. A plausible pre-existing cause was given for the death, and no public data show the drug played a part. The study was stopped anyway, and its results were never released, so nobody outside the company can check either way. The FDA notes that some of the effects seen in healthy volunteers, such as a faster heart rate, low blood pressure and dizziness, might inform how the substance is monitored in people with heart disease or at risk of falls.
What the FDA Found in Its 2024 Review
CJC-1295 has never been an FDA-approved drug, has no USP or NF monograph, and is not a component of an approved product. After the nominations for the 503A compounding list were withdrawn, the FDA removed CJC-1295 from Category 2 of its interim policy as of 27 September 2024 and reviewed it on its own initiative, with a briefing document dated 15 November 2024. FDA's page on bulk substances that may present significant safety risks (content current as of 22 April 2026, read on 3 November 2026) still lists CJC-1295 under "nominated but withdrawn". It names immunogenicity risk for some routes of administration, peptide-related impurities, "serious adverse events associated with CJC-1295 including increased heart rate and systemic vasodilatory reaction", and says "available clinical data are limited". That is stronger wording than the trial papers, which reported no serious adverse reactions, and the page does not say which cases it means.
The briefing also set out the animal and cell findings behind the agency's caution. In rats and dogs given repeated injections of CJC-1295 DAC for up to 14 days, injection site hemorrhage, inflammation and necrosis appeared. In mouse pituitary cell cultures it caused DNA damage, and in mice dosed three times a week for eight weeks it raised the relative weight of the anterior pituitary and damaged pituitary DNA. The FDA found no carcinogenicity studies of any form, and no animal toxicity studies for the forms without DAC. These are animal and cell results; they do not show what happens in people.
On 4 December 2024 the Pharmacy Compounding Advisory Committee voted against adding CJC-1295 to the 503A list: 13 to 0 on the free base and on each of the three DAC forms, and 12 to 1 on the acetate. The votes are advice, not a rule. CJC-1295 was not among the seven peptides the same committee voted on in July 2026, which is covered in the July 2026 FDA peptide vote. For the wider picture of what is and is not permitted, see the research peptides legal status guide.
Who Should Be Most Careful, and Why Supervision Matters
The heart rate rise, the low blood pressure and dizziness, and the Phase 2 death with its unpublished results give anyone with known or suspected cardiovascular disease a specific reason for caution. Elevated growth hormone and IGF-1 carry the risks listed in approved growth hormone labels, including increased risk of neoplasm, glucose intolerance and diabetes, fluid retention and intracranial hypertension, and the FDA found nothing suggesting CJC-1295 would not carry similar risks. The trials enrolled adults only and say nothing about pregnancy or breastfeeding. Anyone on endocrine medication belongs in a clinician's office, not a forum thread.
Supply adds its own variable. The FDA flagged peptide-related impurities and characterisation problems as a concern for this molecule, and CJC-1295 sold as a research chemical carries no assurance of identity, purity or sterility. The general peptide side effects page and are peptides safe cover why supply quality is often the larger variable. For comparison, two related GHRH analogs are covered in tesamorelin side effects and sermorelin side effects.
What This Page Cannot Tell You
There is no controlled follow-up of CJC-1295 beyond a few weeks in healthy adults, DAC or no DAC, and none in people using it for body composition, sleep or wellbeing. Long term CJC-1295 side effects are unknown, not absent, and anyone presenting a confident long-term safety claim in either direction is filling a gap in the record. The CJC-1295 and ipamorelin stack page covers what is known about combining it with a GHRP; no trial has tested the pair, and the ipamorelin side effects page sets out the ipamorelin half. Outside the United States, ABC News reported a coroner's finding that linked a March 2025 death in Australia to CJC-1295 and ipamorelin, and the coroner found the man was taking more than the prescribed dose; what that report and Victoria's health advisory say, and what they do not.
Frequently Asked Questions
Is CJC-1295 safe?
There is no clean answer. In the two published trials, which enrolled 66 healthy adults and gave at most three doses each, no serious adverse reactions were reported, but 94% of people on a single dose reported some adverse event and three people left the studies early. A separate 2006 Phase 2 trial in people with HIV was stopped after a participant died, and the FDA says clinical data are limited and long-term safety is unknown. It has never been an approved drug.
What are the most common CJC-1295 side effects?
Injection site reactions were the most common: irritation, redness, hardening, pain or itching in about 70% of people after one dose, and in every treated person in the repeat-dose trial, all mild. Headache followed (63% on the drug versus 14% on placebo after one dose), then diarrhea (43%), and flushing, warmth or brief low blood pressure (30%). These come from groups of about five people per dose, so each percentage is rough.
How long do CJC-1295 side effects last?
In the trial paper, flushing began within 30 minutes of the injection and was gone within 1 to 2 hours. Injection site reactions were transient, up to several hours, although hardening lasted up to 5 days after higher doses. Headache and diarrhea turned up at various times during the 7 days after a dose. The adverse events at the highest dose resolved after a few hours.
Are there side effects from CJC-1295 without DAC?
Nobody knows from human data. The FDA found no clinical safety information on CJC-1295 without DAC (the free base or acetate forms) and no animal toxicity studies on them either. Every human trial number on this page comes from the DAC version, which binds albumin and stays in the blood for days. Any claim that the no-DAC version is milder is inference, not a tested finding.
Does CJC-1295 cause water retention, joint pain or high blood sugar?
In the Teichman trials none of the subjects had edema, joint pain or glucose intolerance, and blood glucose showed no consistent change. Those trials were short, with at most three doses. Fluid retention, glucose intolerance and diabetes are listed in the labels of approved growth hormone, and the FDA says it found nothing suggesting CJC-1295 would not carry similar risks.
Does CJC-1295 cause cancer?
No human study has tested that. The FDA found no carcinogenicity studies of any CJC-1295 form and said that pituitary overgrowth and tumors from long-term overstimulation cannot be ruled out. It also reported DNA damage in mouse pituitary cells and in the pituitaries of mice given CJC-1295 DAC. Those are animal and cell findings, not proof of a cancer risk in people.
Did someone die in a CJC-1295 clinical trial?
Yes, in a separate Phase 2 study of 192 people with HIV-related visceral obesity. One participant, at a site in Argentina, reportedly had chest discomfort about two hours after an 11th weekly dose and died roughly an hour later. The FDA cites anecdotal reports that the attending physician thought asymptomatic coronary artery disease with plaque rupture was the most likely cause. The study was stopped and its data were never published.
Is CJC-1295 FDA approved or legal to compound?
It has never been FDA approved and is not a component of any approved drug. It has no USP or NF monograph. Its nominations for the 503A compounding list were withdrawn, FDA removed it from Category 2 as of 27 September 2024, and on 4 December 2024 the advisory committee voted against adding it: 13 to 0 for the free base and for each DAC form, and 12 to 1 for the acetate.
Sources (checked 3 November 2026)
- Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab, 2006;91(3):799-805. PMID 16352683; full text read on Zenodo. Checked 3 November 2026.
- Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab, 2006;91(12):4792-4797. PMID 17018654. Abstract read; adverse events taken from the FDA briefing below. Checked 3 November 2026.
- FDA, Pharmacy Compounding Advisory Committee briefing document: CJC-1295-related bulk drug substances, dated 15 November 2024 (meeting of 4 December 2024). fda.gov. Checked 3 November 2026.
- FDA, Final summary minutes, Pharmacy Compounding Advisory Committee, 4 December 2024 (vote results). fda.gov. Checked 3 November 2026.
- FDA, Certain bulk drug substances for use in compounding that may present significant safety risks (content current as of 22 April 2026). fda.gov. Checked 3 November 2026.
- Bernard EJ. Lipodystrophy study halted after patient death. aidsmap, 31 July 2006. aidsmap.com, read through the Internet Archive copy. Checked 3 November 2026.
- Reed Smith, FDA removes certain peptide bulk drug substances from Category 2 of the interim 503A bulks list and sets dates for PCAC review, 4 October 2024 (withdrawn from Category 2 as of 27 September 2024). legal500.com. Checked 3 November 2026.
- Jetté L, Léger R, Thibaudeau K, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology, 2005;146(7):3052-3058. PMID 15817669. Checked 3 November 2026.
Not sure which of these you actually need?
Answer five questions about your goal, experience and budget and the Stack Builder shows you a matched research protocol on screen, with the compounds, cycle shape and vendor picks from the vendors we score.
Build your stack, 2 minutes